A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients

NCT06087419 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia

Interventions

DRUG: chidamide
DRUG: Venetoclax Oral Tablet
DRUG: Inotuzumab Ozogamicin

Sponsor

Institute of Hematology & Blood Diseases Hospital, China